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Low bone mineral densityAbstract Background: COPD is a widely distributed disease with high morbimortality, associated
with important pathologies, among which is osteoporosis. However, osteoporosis is often undiag-
nosed in these patients.
Objectives: To evaluate the prevalence of osteoporosis among COPD patients and to determine
its relation to demographic data and disease severity.
Subjects and methods: This study was conducted on 30 male patients with severe to very severe
COPD, in addition to 30 age and sex matched lifelong nonsmoker healthy volunteers. Spirometric
indices, serum Ca, phosphorous, ALP, albumin, and PTH were measured. BMD was measured by
broadband heel ultrasound method.
Results: Corrected Ca was signiﬁcantly decreased, PTH was signiﬁcantly increased and ALP
showed non-signiﬁcant increase in the COPD group. As regards BMD; BUA, Z-score and T-score
were signiﬁcantly decreased while RRF was signiﬁcantly increased in the COPD group. In addition
56.6% of COPD patients had low BMD. Both COPD group either with normal BMD or with low
BMD were matched as regards all demographic data. VC%, FVC% and FEV1%, BUA, T-score,
598 S.M. Abu-Bakr et al.and Z-score were signiﬁcantly decreased while PTH and RRF were signiﬁcantly increased in the
COPD group with low BMD. Z-score was negatively correlated with FEV1 and PTH while BUA
was positively correlated with ALP and negatively correlated with FEV1/FVC.
Conclusion: Low BMD is prevalent among men with COPD (GOLD stage III–IV) than age
matched males. The degree of the loss of BMD has been found to be proportionate to the COPD
severity. COPD patients with low BMD have threefold increase in fracture risk.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.Introduction
COPD is considered to be a chronic non speciﬁc inﬂammation,
which occurs in the airways, lung parenchyma and pulmonary
vessels. This can cause the activation of inﬂammatory cells and
the release of various inﬂammatory mediators [1]. It is consid-
ered as a syndrome of chronic wasting, and associated with a
chronic inﬂammatory response [2].
Osteoporosis is a systemic skeletal disease characterized by
a low bone mass and/or microarchitectural deterioration of
bone tissue leading to increased bone fragility and increased
fracture risk [3]. Osteoporosis is often disabling in COPD pa-
tients, and may be equally disabling as COPD itself. However,
osteoporosis is often undiagnosed in these patients, and may
impair respiratory function even further, if the patient experi-
ences vertebral compressions and loss of height. Increased
awareness is therefore essential in order to diagnose and treat
bone loss to reduce the risk of fractures [4].Aim of the work
The majority of COPD patients in clinical practice are men of
older age with many under-diagnosed additional risk factors
for osteoporosis. Therefore this study is carried out to evaluate
the prevalence of low BMD (osteopenia or osteoporosis)
among patients with COPD and to determine its relation to
sociodemographic data and to disease severity.Subjects and method
This case control study included 60 individuals. All patients
and healthy controls were males to avoid effect of sex hor-
mones on BMD. Written informed consent was obtained from
all participants before study inclusion, and the study was ap-
proved by the institutional ethical review board of Al-Azhar
University, Faculty of Medicine for Girls. They were divided
into 2 groups:
 COPD group: Included 30 COPD patients with symptoms
of chronic airﬂow limitation and fulﬁlled lung function cri-
teria as set out by the GOLD 2011 [1]. Most of them were
using medications to treat COPD, including b2-agonists
(salbutamol and formetrol), theophyline and inhaled corti-
costeroids (budesonide), none of them was using oral ste-
roids during the time of the study.
 Control group: Included 30 healthy life long non smoker,
sex and age-matched volunteers, who have no symptoms
or signs of any chest disease or other chronic diseases andnormal spirometry. Screening of control subjects for study
inclusion involved a medical history, clinical examination,
serum investigation, electrocardiogram, and spirometry.
Subjects known to have bronchial asthma, interstitial lung
diseases, renal, hepatic, cardiac, metabolic, and endocrinal dis-
orders that could affect serum calcium or BMD were excluded
from the study. Moreover, patients known to have a known
cause for osteoporosis or those receiving systemic corticoste-
roids were excluded from the study.
All subjects were underwent the following
Detailed history taking, complete clinical examination with
special emphasis on musculoskeletal system. Fasting, post-
prandial blood sugar, liver and renal function tests were done.
Measurements of serum calcium (Ca), phosphorus (ph), albu-
min, alkaline phosphatase (ALP) and serum parathormone
hormone (PHT) were done to differentiate between different
types of bone pathology (osteoporosis, osteopenia, osteopetro-
sis, osteomalacia, osteitis ﬁbrosa cystica and Paget disease of
bone), moreover, serum Ca and serum albumin were used to
calculate corrected Ca (cor. Ca) to avoid the effect of hypoal-
buminaemia on serum Ca.
Spirometry was performed using Spirosift spirometry 5000
FUKUDa DENSHI. The following indices were recorded
(VC, FVC, FEV1, FEF25–75 and FEV1/FVC ratio). The highest
values of FEV1 and FVC from at least three technically ac-
cepted measurements were used for analysis [1].
We use broadband heel ultrasound attenuation bone densi-
tometry to measure BMI. The BMD of the left heel bone was
measured. The system incorporates two ultrasound transduc-
ers positioned opposite to each other, touching the lateral as-
pects of the heel that is being placed in between the
transducers. The densitometer measures the broadband ultra-
sonic attenuation (BUA) in dB/MHz of an ultrasound beam
that passes through the calcaneus. It makes an estimation of
BMD and the T-score from this data by the system software.
The T-score quantiﬁes the difference between the patient’s
BMD and the mean value for healthy young adults from the
reference group. According to WHO, the normal value for
T-score is within 1 SD of the mean value for young adults
(1 to +1). Osteopenia is considered when T-score is between
1 and 2.5. Osteoporosis is considered to be present when
the value for BMD is less than 2.5 SD below the mean for
young adults [5].
However, the International Society for Clinical Densitome-
try states that, for premenopausal women, Z-scores (compari-
son with age group rather than peak bone mass) rather than
T-scores should be used, and the diagnosis of osteoporosis in
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metric criteria alone [6]. So in this study we diagnose low BMD
on the bases of both T-score and Z-score.
Statistical presentation and analysis of the study data were
conducted, using SPSS V17. p> 0.05 is considered non-signif-
icant, p< 0.05 is considered signiﬁcant while p 6 0.01 is con-
sidered highly signiﬁcant.
Results
Table 1 shows that Corrected Ca was signiﬁcantly decreased (p
0.05), while PTH was signiﬁcantly increased (p< 0.01) and
ALP was non-signiﬁcantly increased in the COPD group (p
0.052). BUA, Z-score and T-score were signiﬁcantly decreased
(p< 0.01) while RRF was signiﬁcantly increased in the COPD
group than control group.
Table 2 shows that Z-score was negatively correlated with
FEV1, RRF and PTH and positively correlated with BUA
and T-score. T-score was positively correlated with BUA and
negatively correlated with RRF. BUA was negatively corre-
lated with RRF. On the other hand RRF was not correlated
with sociodemographic data, spirometric-indices, and bone
proﬁle (p> 0.05).
COPD group is divided into two subgroups: COPD with
low BMD 17 patients (56.6%) and COPD with normal
BMD 13 patients (43.4%). Both groups were matched as re-
gards all sociodemographic data. VC%, FVC% and
FEV1%, BUA, T-score and Z-score were signiﬁcantly de-
creased while PTH and RRF were signiﬁcantly increased in
the COPD group with low BMD than the COPD group with
normal BMD (p< 0.01) (Table 3).Table 1 Comparison of all variables between COPD group
and control group.
Item COPD (No. 30) Control (No. 30) t p
Mean ± SD Mean ± SD
Demographic-data
Age 60.9 ± 5.4 59.6 ± 5.6 2.25 0.06
BMI 26.5 ± 5.5 25.9 ± 2.5 2.28 0.052
D.D 12.9 ± 9.3 – – –
S. index 914.0 ± 745.5 – – –
Spirometric-indices%
VC% 34.8 ± 12.6 84.0 ± 8.8 17.4 <0.01
FEV1/FVC 61.7 ± 9.1 84.8 ± 6.3 16.3 <0.01
FEV1 24.2 ± 10.6 106.9 ± 23.4 17.5 <0.01
FVC 27.7 ± 12.3 99.0 ± 20.3 11.4 <0.01
FEF25–75 19.5 ± 14.0 80.6 ± 7.8 20.7 <0.01
Bone proﬁle
Cor.Ca 9.0 ± 0.8 9.5 ± 0.6 0.28 0.02
Ph 3.8 ± 0.4 4.0 ± 0.39 1.65 0.11
ALP 196.0 ± 66.4 167.0 ± 43.2 2 0.052
PTH 89.6 ± 50.1 53.7 ± 11.8 3.8 <0.01
BMD
BUA 57.3 ± 7.3 65.1 ± 4.7 4.9 <0.01
Z score 1.4 ± 1.1 0.28 ± 0.9 6.3 <0.01
T score 2.3 ± 1.1 0.8 ± 0.9 5.45 <0.01
RRF 7.0 ± 8.0 2.1 ± 1.23 3.33 <0.01Discussion
COPD and osteoporosis are strongly associated because of
common risk factors such as age, smoking, and inactivity. In
addition, COPD-related systemic inﬂammation, vitamin D
deﬁciency, and the use of systemic corticosteroids enhance
ongoing bone destruction [7].
In this study BMD was assessed by broadband heel ultra-
sound attenuation bone densitometer because it is readily
available and easy to perform, but this method is not consid-
ered a gold standard as dual energy absorptiometry (DXA),
however, it has a comparable accuracy to DXA [8].
In this study COPD patients and control subjects were age,
sex and BMI matched (Table 1), all subjects in this study were
male to avoid the effects of sex hormones in BMD. The inci-
dence of osteoporosis is higher in women than in men, and it
could be expected that women with COPD would be even
more susceptible to develop osteoporosis than women with
normal lung function [4]. Moreover, the most important risk
factors for osteoporosis are advanced age (in both men and
women) and female sex; oestrogen deﬁciency following meno-
pause or oophorectomy is correlated with a rapid reduction in
BMD, while in men, a decrease in testosterone levels has a
comparable (but less pronounced) effect [9].
This study demonstrated that corrected serum Ca, ph, ALP
and PTH for COPD group and control group were in normal
ranges, however the corrected serum Ca was signiﬁcantly de-
creased, ALP was non-signiﬁcantly increased, while PTH
was signiﬁcantly increased in the COPD group than the con-
trol group (Table 1). These ﬁndings of bone proﬁle indicate
that all COPD patients and control subjects in this study did
not have any bone pathology other than osteoporosis or
osteopenia.
The current study showed Z-score (1.46 ± 1.15) for
COPD and (0.28 ± 0.97) for control group, and T-score
(2.36 ± 1.17) for COPD and (0.80 ± 0.96) for control
group. In addition, the 2 indices were signiﬁcantly lower in
the COPD group than the control group (p< 0.001). More-
over, both T-score and Z-score for the COPD group were in
osteopenic range. On the other hand RRF was signiﬁcantly
higher in the COPD group than the control group
(7.06 ± 8.00 and (2.14 ± 1.23 respectively) (p< 0.01) (Ta-
ble 1). This ﬁnding means that COPD patients had threefold in-
creased risk of fracture than healthy subjects of same age and
sex. Jørgensen et al. [4] reported that the mean ± SD of T-score
at lumbar spine was 1.54 ± 7 1.27 while that at femoral neck
1.49 ± 7 1.63.
In the current study Z-score was negatively correlated with
FEV1%, RRF and PTH, while it positively correlated with
BUA and T-score (p< 0.01). T-score was positively correlated
with BUA and negatively correlated with RRF. Lastly BUA
was negatively correlated with RRF (Table 3).
Correlation of BMD with BMI had been reported in sev-
eral studies [10–15]. Moreover age, and PTH level were signif-
icant independent correlates for osteoporosis [10,11].
Jorgensen and Schwartz [16] reported that the BMD was
strongly correlated with reduced FFV1%. Scanlon et al. [17]
have found age > 56 years and female sex to be independent
correlates of osteoporosis in COPD. Different results were re-
ported by WHO [5] that PTH is negatively associated with
BMD.
Table 2 Correlation between BMD-Indices and different variables among COPD group.
Item Z-score T-score BUA RRF
r p r p r p r p
Age 0.07 0.72 0.26 0.16 0.35 0.06 0.25 0.18
Smoking index 0.10 0.60 0.19 0.31 0.14 0.45 0.21 0.28
COPD duration 0.23 0.23 0.25 0.19 0.26 0.17 0.17 0.38
BMI 0.20 0.29 0.01 0.94 0.12 0.52 0.01 0.94
VC% 0.29 0.13 0.23 0.23 0.18 0.36 0.21 0.27
FEV1/FVC% 0.09 0.66 0.05 0.78 0.08 0.69 0.11 0.56
FEV1% 0.39 0.03* 0.33 0.07 0.23 0.22 0.33 0.08
FVC% 0.35 0.06 0.26 0.17 0.19 0.33 0.16 0.39
FEF25–75% 0.28 0.14 0.27 0.16 0.18 0.34 0.30 0.11
Corrected Ca 0.22 0.25 0.15 0.43 0.12 0.53 0.07 0.70
Serum ph 0.16 0.39 0.06 0.75 0.10 0.61 0.04 0.85
ALP 0.31 0.10 0.26 0.17 0.26 0.16 0.16 0.39
PTH 0.35 0.04* 0.16 0.39 0.12 0.54 0.05 0.80
BUA 0.76 <0.01* 0.94 <0.01* – – – –
T-score 0.83 <0.01* – – – – – –
RRF 0.73 <0.01* 0.86 <0.01* 0.84 <0.01 – –
* p value is signiﬁcant.
Table 3 Comparison of all variables between patients with normal and lowBMD among COPD group.
Item COPD with low BMD (No. 17) COPD with normal
BMD (No. 13)
t p
Mean ± SD Mean ± SD
Sociodemographic data
Age 61.4 ± 6.3 60.3 ± 4.3 0.51 0.61
BMI 27.1 ± 6.6 25.7 ± 4.0 0.71 0.48
D.D 14.2 ± 10.5 11.3 ± 7.7 0.85 0.40
S. index 902. 4 ± 859.8 929.2 ± 597.7 0.1 0.92
Spirometric-indices%
VC 29.2 ± 10.5 39.1 ± 12.8 2.30 0.03*
FVC 21.9 ± 8.7 32.1 ± 13.1 2.43 0.02*
FEV1 19.9 ± 7.8 27.5 ± 11.5 2.10 0.05
FEV1/FVC 63.7 ± 8.4 60.3 ± 9.6 1.01 0.32
FEF 25–75 16.5 ± 10.1 21.9 ± 16.3 1.05 0.30
Bone proﬁle
Cor. Ca 8.95 ± 0.8 9.2 ± 0.9 0.89 0.38
ALP 208.5069.8± 179.8 ± 60.5 1.18 0.25
PTH 105.71 ± 48.2 68.54 ± 46.1 2.13 0.04
BMD
BUA 53.3 ± 6.7 62.5 ± 4.2 4.30 0.01*
T-score 3.0 ± 0.9 1.4 ± 0.7 4.84 0.00*
Z-score 1.4 ± 1.1 0.28 ± 0.9 6.3 0.01*
RRF 10.07 ± 9.6 3.1 ± 1.3 2.9 0.00*
* p value is signiﬁcant.
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ther classify COPD patients into 2 groups; COPD with normal
BMD and COPD with low BMD. Our results showed low
BMD (osteopenia or osteoporosis) in approximately 56.66%
(17/30) of the COPD group. None of these patients suffered
from any symptoms related to fracture or any history of previ-
ous fractures. Thus, a large number of COPD patients have
established osteopenia or osteoporosis and they do not receive
any treatment.
Parthasarathi et al. [8] found that 73% of COPD patients
(GOLD- IV) had low BMD and 27% had normal BMD. Thisslightly higher prevalence of low BMD reported by them may
be attributed to the fact that their patients were male and fe-
male (35:2 ratio) while our study was conducted only on male
subjects and also their patients were more older
(65.32 ± 9.58 years) than those in the current study. Similar
high prevalence of osteoporosis among COPD patients was re-
ported by Graat-Verboom et al. [11]as they concluded that
among clinically stable COPD patients, 51% had radiologic
evidence of osteoporosis. Moreover, combining the results of
local DXA with spinal X-rays augmented the proportion of
COPD patients with osteoporosis compared with both
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ported higher prevalence of low BMD among COPD as they
found reduction of BMD in about 50% of COPD patients.
TORCH Study Group [18], (Towards a Revolution in COPD
Health) over half of the COPD patients recruited (out of the
6000 patients) had osteoporosis or osteopenia as determined
by DXA. Jørgensen et al. [4] reported that 40.74% COPD pa-
tients were diagnosed as having osteoporosis, 29.62% were
osteopenic and 29.62% had normal BMD. Combining history
of fracture, X-rays and DXA, they found that 44.8% of COPD
patients were osteoporotic, 22.4% were osteopenic and 25.9%
had normal BMD.
Different prevalence of osteoporosis in COPD patients had
been reported by different investigators [19–23]. This may be
attributed to different study population characteristics (age,
sex, smoking index, GOLD stages), different BMD diagnostic
methods. It may also attributed to variable genetic susceptibil-
ity to osteoporosis or different resident areas (sunny vs. foggy
areas).
Shepherd et al. [24] reported that the prevalence of low
BMD in COPD patients varies between 9–69% and 27–67%,
respectively, depending on the diagnostic methods used, the
population studied, and the severity of the underlying respira-
tory disease. In COPD patients, the prevalence of osteoporosis
is assumed to be two- to ﬁvefold higher than that in age-
matched subjects without airﬂow obstruction. In a recently
developed screening tool for males at risk for osteoporosis,
the presence of COPD is one of the parameters increasing this
risk almost fourfold times.
In this study COPD patients with low BMD had more age,
BMI and disease duration than those with normal BMD, how-
ever this difference was non-signiﬁcant (p> 0.05). No differ-
ence in smoking index could be detected between COPD
patients with normal BMD and those patients with low
BMD in (Table 3). This does not indicate that smoking is
not a risk factor of osteoporosis, but it might suggest that, in
addition to a genetic component, osteoporosis is strongly af-
fected by environmental factors that might outweigh the ef-
fects of smoking on the bones. This result conﬁrmed that
reported by Jørgensen et al. [4] as they concluded that there
is no differences in tobacco pack years could be detected be-
tween the osteoporotic and non-osteoporotic COPD patients.
In this study the COPD group with low BMD also demon-
strated signiﬁcant decrease in VC%, FVC% and FEV1% than
those with normal BMD (p< 0.05) (Table 3). Different results
were reported by Jørgensen et al. [4] that no statistically signif-
icant differences in the pulmonary function were detected be-
tween osteoporotic, osteopenic, and normal BMD COPD
patients. Parthasarathi et al. [8] revealed that the disease sever-
ity FEV1% was equal in magnitude between both groups (p
0.09).
The current study showed that T-score and Z-score were
decreased signiﬁcantly in COPD with low BMD than those
with normal BMD (0.000), however, T-score was in osteopo-
rotic range while Z-score was in osteopenic range
(3.04 ± 0.99 and 1.4 ± 1.1 respectively), which means that
T-score is more sensitive for assessment of BMD than Z-score
as recommended by WHO 2007. Similar result was reported by
Parthasarathi et al. [8] as they found that the mean ± SD of T-
scores was (2.10 ± 0.57) for COPD with low BMD and
(0.51 ± 0.27) for those with normal BMD with signiﬁcant dif-
ference between both groups (p< 0.001).Moreover, RRF was signiﬁcantly increased in the COPD
group with low BMD than those with normal BMD
(10.07 ± 9.6 and 3.1 ± 1.3 respectively) (p< 0.01) (Table 3)
whichmeans that COPDpatients with lowBMDhadmore than
threefold increase in fracture risk than COPDpatients with nor-
mal BMD. This fracture would increase cost of COPDmanage-
ment, hospitalization, morbidity and mortality. Jørgensen et al.
[4] reported that there is a clear tendency towards increased frac-
ture risk in COPD as the percentage of individuals with fracture
increases from 6.3% in the group with normal BMD, 18.8% in
the osteopenic group to 31.8% in the osteoporotic group.
Finally, this study has some limitations that need to be
mentioned. Firstly: All the patients were in GOLD III/IV stage
and we have not noted the BMD of the early COPD patients.
Hence, the actual prevalence of osteoporosis/osteopenia in
overall COPD population cannot be detected from our obser-
vation. Secondly with a small number of COPD patients, it is
not possible to make any comparison between the osteopenic
and osteoporotic patients.
Conclusions
 The present study showed a high prevalence of low BMD
(56.6%) among men with COPD (GOLD stage III–IV)
than age and sex matched healthy individuals and the
degree of the loss of BMD has been found to be proportion-
ate to the severity of the disease.
 COPD patients with low BMD have threefold increase in
fracture risk than COPD patients with normal BMD.Recommendation
 Despite the limitations of this study there is no doubt that
low BMD is a major problem in COPD patients, and
patients with severe COPD should have performed diagnos-
tic X-ray/DXA in order to diagnose osteoporosis.
 Assessment of low BMD in COPD is important from a clin-
ical point of view as appropriate intervention may lessen the
morbidity of the COPD patients.
 Osteopenic patients should be followed closely in order to
start anti-osteoporotic treatment as soon as necessary
before fractures occur. Further, if the patient is continu-
ously treated with glucocorticoids, treatment should be ini-
tiated already in osteopenic patients according to
international recommendations.
 Chest physicians should be aware of the high prevalence of
osteoporosis in patients with COPD, especially in elder
COPD patients with and/or an increased PTH level.Conﬂicts of interest
None declared.
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